(Q51951517)

18 April 2018

title

Generalized anxiety disorder: prevalence, burden, and cost to society. (English)

1 reference

18 April 2018

generalized anxiety disorder

main subject

0 references

0 references

1 reference

18 April 2018

publication date

1 January 2002

1 reference

18 April 2018

published in

Depression and Anxiety

1 reference

18 April 2018

volume

1 reference

18 April 2018

issue

1 reference

18 April 2018

page(s)

162-171

1 reference

18 April 2018

Psychiatric comorbidity in patients with generalized anxiety disorder.

cites work

1 reference

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

21 January 2018

1 reference

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients

21 January 2018

1 reference

Utilization of medical specialists by anxiety disorder patients

21 January 2018

1 reference

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

21 January 2018

1 reference

Emergence of depressive symptoms in patients receiving alprazolam for panic disorder

21 January 2018

1 reference

Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?

21 January 2018

1 reference

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

Health care costs associated with depressive and anxiety disorders in primary care.

21 January 2018

1 reference

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

21 January 2018

1 reference

Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin.

21 January 2018

1 reference

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

7 January 2021

Help-Seeking for Psychiatric Disorders

1 reference

7 January 2021

One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up.

1 reference

7 January 2021

Reliability of DSM-III-R Anxiety Disorder Categories

1 reference

7 January 2021

Economic costs of anxiety disorders.

1 reference

7 January 2021

Anxiety disorders in major depression

1 reference

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

7 January 2021

The economic burden of anxiety disorders in the 1990s

1 reference

7 January 2021

Estimating the prevalence of mental and somatic disorders in the community: aims and methods of the German National Health Interview and Examination Survey.

1 reference

7 January 2021

Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS).

1 reference

7 January 2021

The epidemiology of DSM-III-R bipolar I disorder in a general population survey

1 reference

7 January 2021

The epidemiology of generalized anxiety disorder.

1 reference

7 January 2021

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

1 reference

7 January 2021

A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder

1 reference

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

7 January 2021

Therapeutic advances: paroxetine for the treatment of social anxiety disorder

1 reference

7 January 2021

An overview of generalized anxiety disorder: disease state--appropriate therapy

1 reference

7 January 2021

Comorbidity in generalized anxiety disorder

1 reference

7 January 2021

Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care

1 reference

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

7 January 2021

British psychiatric morbidity survey

1 reference

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

7 January 2021

The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder

1 reference

7 January 2021

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

7 January 2021

Cost of anxiety disorders: impact of comorbidity.

1 reference

7 January 2021

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey.

1 reference

7 January 2021

Prevalence of mental disorders and psychosocial impairments in adolescents and young adults

1 reference

7 January 2021

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.10065

1 reference

18 April 2018

1 reference

18 April 2018